Investing.com -- WingStop has been added to the Wedbush Best Ideas List, with the firm forecasting strong growth potential for the company in 2025. According to Wedbush analysts, WingStop is "well ...

Investing.com -- Wedbush upgraded PulteGroup Inc (NYSE:PHM) to "outperform" from "neutral" given an overdone stock price decline and strong catalysts for growth. Shares were up 2.1% at $110.

Gov. Geoff Duncan from being associated with the party, pointing to his alleged efforts to undermine Republican candidates. The decision, approved unanimously, was finalized on Jan. 6, cutting ...

Arhaus, Inc. (NASDAQ:ARHS – Free Report) – Investment analysts at Wedbush lifted their FY2024 earnings per share estimates for Arhaus in a research note issued to investors on Friday ...

As previously reported, Wedbush initiated coverage of Innodata (INOD) with an Outperform rating and $48 price target The digital services and data transformation company is currently the partner ...

LOS ANGELES--(BUSINESS WIRE)--Wedbush Securities, a prominent diversified independent financial services provider, is pleased to announce that Alex Froloff has joined the firm as a Financial ...

Investing.com -- WingStop has been added to the Wedbush Best Ideas List, with the firm forecasting strong growth potential for the company in 2025. According to Wedbush analysts, WingStop is ...

The Georgia Republican Party has booted longtime President-elect Trump critic former Lt. Gov. Geoff Duncan (R), who backed Vice President Harris’s 2024 bid for the White House. A resolution from ...

Wedbush analyst Brian Violino raised the firm’s price target on Fannie Mae to $1 from 50c and keeps an Underperform rating on the shares. Wedbush says shares of both Fannie Mae (FNMA) and ...

Investing.com-- Wedbush added Uber Technologies Inc (NYSE:UBER) to its "best ideas list" given attractive risk/reward dynamics with shares trading at lower multiple. Uber shares trading for only ...

Wedbush is not changing the firm’s positive bias on Viridian Therapeutics (VRDN) after its competitor Acelyrin (SLRN) hosted an investor event to disclose lonigutamab Phase 2 data and plans for ...